HP802-247 is an investigational allogeneic living cell bioformulation that contains keratinocytes and fibroblasts currently under development for venous leg ulcers treatment.
Healthpoint Biotherapeutics chief medical officer Bert Slade said, "We are very pleased that the trial results are appearing in such a prestigious general medical journal, thus recognizing the impact chronic wounds have across multiple medical specialties."
The Phase 2b trial has been designed to know the effectiveness of two cell concentrations and two dosing frequencies of HP802-247, when combined with standard care, compared to control plus standard care, in healing venous leg ulcers over a 12-week treatment period.
The randomized, double blind, dose-finding study enrolled 228 subjects across 35 investigational centers in the US.
Venous Leg Ulcers are caused by swelling and inflammation secondary to blockage or backflow in the veins of the legs.
The study results are also accompanied by expert commentary commissioned by the journal.